AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29601846 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver burden assessment at baseline, 3 months, and 12 months post-arrest using the Infant Toddler Quality of Life Questionnaire and the Child Health Questionnaire.
Number of subjects: 138
Study 29601846 — intervention group
Group type: EXPERIMENTAL
Intervention: Child functioning assessment using the Vineland Adaptive Behaviour Scales Second Edition (VABS‐II), Paediatric Overall Performance Category (POPC), and Paediatric Cerebral Performance Category (PCPC) scales.
Number of subjects: 138
Study 29601846 — intervention group
Group type: EXPERIMENTAL
Intervention: Global functioning assessment at 3 months post-arrest.
Number of subjects: 138
Study 24361322 — intervention group
Group type: EXPERIMENTAL
Intervention: Red blood cell (RBC) transfusion
Number of subjects: 61
Study 22863328 — intervention group
Group type: EXPERIMENTAL
Intervention: 5·0×10(6) cells per mL every 7 days
Number of subjects: 205
Study 22863328 — intervention group
Group type: EXPERIMENTAL
Intervention: 5·0×10(6) cells per mL every 14 days
Number of subjects: 205
Study 22863328 — intervention group
Group type: EXPERIMENTAL
Intervention: 0·5×10(6) cells per mL every 7 days
Number of subjects: 205
Study 22863328 — intervention group
Group type: EXPERIMENTAL
Intervention: 0·5×10(6) cells per mL every 14 days
Number of subjects: 205
Study 22863328 — intervention group
Group type: COMPARATOR
Intervention: Vehicle alone every 7 days
Number of subjects: 205
Study 19995096 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic insulin aspart 30 twice daily
Number of subjects: 0
Study 19995096 — intervention group
Group type: COMPARATOR
Intervention: Insulin aspart three times daily with or without NPH insulin
Number of subjects: 0
Study 19408486 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzymatic debridement using a proteolytic enzyme complex from pineapple stems
Number of subjects: 22
Study 19408486 — intervention group
Group type: COMPARATOR
Intervention: Standard of care methods
Number of subjects: 22
Study 16485522 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity exercise in trained subjects (T)
Number of subjects: 17
Study 16485522 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise in trained subjects (T)
Number of subjects: 17
Study 16485522 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity exercise in untrained subjects (UT)
Number of subjects: 17
Study 16485522 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise in untrained subjects (UT)
Number of subjects: 17
Study 12439117 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-infectious IBS or functional diarrhoea group (n=24)
Number of subjects: 42
Study 12439117 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=18)
Number of subjects: 42
Study 10480584 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended release albuterol sulfate
Number of subjects: 46
Study 10480584 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol xinafoate
Number of subjects: 46
Study 7586313 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg intravenous amiodarone
Number of subjects: 342
Study 7586313 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg intravenous amiodarone
Number of subjects: 342
Study 7586313 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg intravenous amiodarone
Number of subjects: 342
Study 7586313 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of intravenous amiodarone
Number of subjects: 342
Study 7586313 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amiodarone
Number of subjects: 342
Study 2334628 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized lignocaine
Number of subjects: 20
Study 2334628 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 20
Study 2334628 — intervention group
Group type: COMPARATOR
Intervention: Comparison of lignocaine vs saline
Number of subjects: 20
Study 111610 — intervention group
Group type: EXPERIMENTAL
Intervention: Azlocillin
Number of subjects: 20
Study 111610 — intervention group
Group type: EXPERIMENTAL
Intervention: Mezlocillin
Number of subjects: 20
Study 111610 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticarcillin
Number of subjects: 20
Study 30865295 — intervention group
Group type: EXPERIMENTAL
Intervention: Couple therapy
Number of subjects: 554
Study 31666059 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic drugs awareness
Number of subjects: 1237
Study 31666059 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic substitution knowledge
Number of subjects: 1237
Study 31666059 — intervention group
Group type: EXPERIMENTAL
Intervention: Understanding of legislation
Number of subjects: 1237
Study 31666059 — intervention group
Group type: EXPERIMENTAL
Intervention: Legislative rules awareness
Number of subjects: 1237
Study 31666059 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-related problems awareness
Number of subjects: 1237
Study 27816543 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical assistance programs (PAPs) for smoking cessation medications
Number of subjects: 560
Study 27816543 — intervention group
Group type: EXPERIMENTAL
Intervention: PAP-eligible smokers
Number of subjects: 560
Study 25403016 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhancing Connections Program (5, 1-hr educational counseling sessions at 2-week intervals)
Number of subjects: 176
Study 25403016 — intervention group
Group type: COMPARATOR
Intervention: Control group (received a booklet and phone call on communicating and supporting their child about the mother's cancer)
Number of subjects: 176
Study 23550199 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guided percutaneous needle aspiration along with metronidazole
Number of subjects: 57
Study 23550199 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole alone
Number of subjects: 57
Study 21844082 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (2 g/d)
Number of subjects: 199
Study 21844082 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199
Study 19852201 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 34
Study 19852201 — intervention group
Group type: COMPARATOR
Intervention: Terbutaline
Number of subjects: 34
Study 19852201 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide + Terbutaline
Number of subjects: 34
Study 19852201 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 34
Study 16466310 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 14755039 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with BV
Number of subjects: 890
Study 14755039 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 890
Study 11824362 — intervention group
Group type: EXPERIMENTAL
Intervention: Scientific research carried out by surgical department heads
Number of subjects: 27
Study 11824362 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrospective studies and case studies
Number of subjects: 27
Study 11824362 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in prospective randomized studies
Number of subjects: 27
Study 11824362 — intervention group
Group type: EXPERIMENTAL
Intervention: Publications in German
Number of subjects: 27
Study 11824362 — intervention group
Group type: EXPERIMENTAL
Intervention: Publications in English
Number of subjects: 27
Study 11824362 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved know-how and coordination centers
Number of subjects: 27
Study 11824362 — intervention group
Group type: EXPERIMENTAL
Intervention: Lack of time and documentation issues
Number of subjects: 27
Study 9423917 — intervention group
Group type: EXPERIMENTAL
Intervention: Lid speculum used during surgery (n = 108)
Number of subjects: 220
Study 9423917 — intervention group
Group type: COMPARATOR
Intervention: No lid speculum used during surgery (n = 112)
Number of subjects: 220
Study 8201689 — intervention group
Group type: EXPERIMENTAL
Intervention: In situ ESWL (Dornier HM3)
Number of subjects: 76
Study 8201689 — intervention group
Group type: EXPERIMENTAL
Intervention: In situ ESWL (Siemen's Lithostar)
Number of subjects: 76
Study 8201689 — intervention group
Group type: EXPERIMENTAL
Intervention: Ureteroscopy
Number of subjects: 76
Study 3142430 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase (SK) intravenously (group 1)
Number of subjects: 163
Study 3142430 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-chain rt-PA (group 2)
Number of subjects: 163
Study 3142430 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-chain rt-PA (group 3)
Number of subjects: 163
Study 3142430 — intervention group
Group type: EXPERIMENTAL
Intervention: rt-PA followed by intracoronary streptokinase (group 4)
Number of subjects: 163
Study 3142430 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyl enzyme (group 5)
Number of subjects: 163
Study 3142430 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase (SK)
Number of subjects: 163
Study 29324233 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 0
Study 29324233 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26873582 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational health promotion intervention adapted for persons with SMI
Number of subjects: 20
Study 25708991 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention bias modification treatment (ABMT)
Number of subjects: 589
Study 25708991 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention bias modification treatment (ABMT) delivered in clinic
Number of subjects: 589
Study 25708991 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention bias modification treatment (ABMT) delivered at home
Number of subjects: 589
Study 25708991 — intervention group
Group type: COMPARATOR
Intervention: Control training
Number of subjects: 589
Study 23917696 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiac plexus block performed after pharmacological control of pain (Group II)
Number of subjects: 60
Study 23917696 — intervention group
Group type: COMPARATOR
Intervention: Celiac plexus block performed first followed by pharmacotherapy (Group I)
Number of subjects: 60
Study 20701121 — intervention group
Group type: EXPERIMENTAL
Intervention: Tpanax Notoginseng pills (4 g, twice daily)
Number of subjects: 60
Study 20701121 — intervention group
Group type: EXPERIMENTAL
Intervention: Tpanax Notoginseng pills (4 g, twice daily) and Lornoxicam injection (8 mg, once daily)
Number of subjects: 60
Study 20701121 — intervention group
Group type: EXPERIMENTAL
Intervention: Tpanax Notoginseng pills (4 g, twice daily), Lornoxicam injection (8 mg, once daily), and Tongmai decoction (200 ml, twice daily)
Number of subjects: 60
Study 20701121 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 60
Study 18445842 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib plus dacarbazine
Number of subjects: 101
Study 18445842 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus dacarbazine
Number of subjects: 101
Study 16571610 — intervention group
Group type: EXPERIMENTAL
Intervention: Breas PV 10i
Number of subjects: 27
Study 16571610 — intervention group
Group type: EXPERIMENTAL
Intervention: Autoset Spirit
Number of subjects: 27
Study 16571610 — intervention group
Group type: EXPERIMENTAL
Intervention: RemStar Auto
Number of subjects: 27
Study 16571610 — intervention group
Group type: COMPARATOR
Intervention: All APAP devices
Number of subjects: 27
Study 14659344 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of synthetic progestin (nomegestrol acetate or NOMAC)
Number of subjects: 0
Study 14659344 — intervention group
Group type: COMPARATOR
Intervention: Continuous treatment with nomegestrol acetate (NOMAC)
Number of subjects: 0
Study 14659344 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of NOMAC
Number of subjects: 0
Study 11143933 — intervention group
Group type: EXPERIMENTAL
Intervention: Closure of the visceral peritoneum
Number of subjects: 577
Study 11143933 — intervention group
Group type: COMPARATOR
Intervention: Nonclosure of the visceral peritoneum
Number of subjects: 577
Study 8775936 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 0
Study 8775936 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary angioplasty
Number of subjects: 0
Study 8775936 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrates
Number of subjects: 0
Study 8775936 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 0
Study 8775936 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blockers
Number of subjects: 0
Study 8775936 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting-enzyme inhibitors
Number of subjects: 0
Study 8775936 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium
Number of subjects: 0
Study 8775936 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiarrhythmic agents
Number of subjects: 0
Study 8775936 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombotic agents
Number of subjects: 0
Study 1385826 — intervention group
Group type: EXPERIMENTAL
Intervention: Patch test reactions to 11 common organic allergens
Number of subjects: 0
Study 1385826 — intervention group
Group type: COMPARATOR
Intervention: Patch test control (0.4% phenol and 50% glycerin in 0.9% saline)
Number of subjects: 0
Study 1385826 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesional skin samples
Number of subjects: 0
Study 6338636 — intervention group
Group type: EXPERIMENTAL
Intervention: Antilymphoblast globulin (ALG)
Number of subjects: 67
Study 6338636 — intervention group
Group type: COMPARATOR
Intervention: Control (azathioprine and prednisone without ALG)
Number of subjects: 67
Study 30778427 — intervention group
Group type: EXPERIMENTAL
Intervention: CT scans reviewed for anatomical variations
Number of subjects: 200
Study 29121274 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (BEV)/irinotecan (IRI)
Number of subjects: 170
Study 29121274 — intervention group
Group type: COMPARATOR
Intervention: Standard temozolomide
Number of subjects: 170
Study 29121274 — intervention group
Group type: COMPARATOR
Intervention: Standard temozolomide with crossover to BEV second-line therapy
Number of subjects: 170
Study 26698820 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy (78 weeks)
Number of subjects: 100
Study 25271049 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blocker use in prior MI cohort
Number of subjects: 14677
Study 25271049 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blocker use in known atherothrombotic disease cohort
Number of subjects: 14677
Study 25271049 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blocker use in risk factors alone cohort
Number of subjects: 14677
Study 21592719 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice interactive tailored patient assessment tool (ITPA)
Number of subjects: 196
Study 21592719 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ITPA)
Number of subjects: 196
Study 21592719 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurses consultations
Number of subjects: 196
Study 21592719 — intervention group
Group type: COMPARATOR
Intervention: Physicians consultations
Number of subjects: 196
Study 21180869 — intervention group
Group type: EXPERIMENTAL
Intervention: National manovacuometer
Number of subjects: 18
Study 21180869 — intervention group
Group type: COMPARATOR
Intervention: Foreign manovacuometer
Number of subjects: 18
Study 21180869 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of both manovacuometers
Number of subjects: 18
Study 17979860 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BTX‐A) injections (3 injections at 0, 6, and 18 months; dose 0.5-2.1 units/kg, mean 1.5 [SD 0.18]; dilution 100 units/0.5 ml)
Number of subjects: 42
Study 17979860 — intervention group
Group type: COMPARATOR
Intervention: Delayed group (2 injections at 6 and 18 months)
Number of subjects: 42
Study 14717945 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol therapy (0.5 microg/48 h) plus oral calcium supplementation (0.5 g/day) for 1 year
Number of subjects: 86
Study 14717945 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol therapy
Number of subjects: 86
Study 14717945 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 11779900 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomethiazole (68 mg/kg IV over 24 hours)
Number of subjects: 1198
Study 11779900 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1198
Study 11779900 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomethiazole
Number of subjects: 1198
Study 9639500 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl-cysteine (NAC)
Number of subjects: 0
Study 9639500 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl-cysteine (NAC) plus interleukin-2
Number of subjects: 0
Study 7827649 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 different drug regimes
Number of subjects: 0
Study 2683908 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg administered sublingually)
Number of subjects: 12
Study 2683908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2683908 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 12
Study 31855303 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate or azathioprine
Number of subjects: 38
Study 29620663 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium salt (LSSalt) diet
Number of subjects: 126
Study 29620663 — intervention group
Group type: COMPARATOR
Intervention: Normal salt (NSalt) diet
Number of subjects: 126
Study 28963313 — intervention group
Group type: EXPERIMENTAL
Intervention: e-learning
Number of subjects: 247
Study 28963313 — intervention group
Group type: EXPERIMENTAL
Intervention: group training
Number of subjects: 247
Study 28963313 — intervention group
Group type: COMPARATOR
Intervention: usual care
Number of subjects: 247
Study 28963313 — intervention group
Group type: COMPARATOR
Intervention: all groups
Number of subjects: 247
Study 25194517 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D navigational feedback on sawbones
Number of subjects: 15
Study 25194517 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D navigational feedback on cadavers
Number of subjects: 15
Study 25194517 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 15
Study 24517212 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX + hydroxychloroquine + sulphasalazine + prednisone (arm 1)
Number of subjects: 610
Study 24517212 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX + adalimumab (arm 2)
Number of subjects: 610
Study 24517212 — intervention group
Group type: EXPERIMENTAL
Intervention: Early remission (DAS <1.6 after 4 months)
Number of subjects: 610
Study 24517212 — intervention group
Group type: EXPERIMENTAL
Intervention: Early remission
Number of subjects: 610
Study 24517212 — intervention group
Group type: COMPARATOR
Intervention: Patients not in early remission
Number of subjects: 610
Study 21371496 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise
Number of subjects: 135
Study 21371496 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 135
Study 18717710 — intervention group
Group type: EXPERIMENTAL
Intervention: Classic ketogenic diet (KD) with glucose (60 g/day)
Number of subjects: 20
Study 18717710 — intervention group
Group type: COMPARATOR
Intervention: Classic ketogenic diet (KD) with saccharin
Number of subjects: 20
Study 16958397 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-expandable metallic stent placement
Number of subjects: 19
Study 14698679 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticotropin-releasing hormone (CRH) 100 microg bolus injection
Number of subjects: 12
Study 14698679 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) 150 microg infusion
Number of subjects: 12
Study 14698679 — intervention group
Group type: COMPARATOR
Intervention: Normal saline infusion (control)
Number of subjects: 12
Study 11085402 — intervention group
Group type: EXPERIMENTAL
Intervention: Canada411
Number of subjects: 346
Study 11085402 — intervention group
Group type: COMPARATOR
Intervention: InfoSpace
Number of subjects: 346
Study 8829056 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic presacral neurectomy (LPSN)
Number of subjects: 68
Study 8829056 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic uterine nerve ablation (LUNA)
Number of subjects: 68
Study 1573045 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone 5 mg three times a day for the first week, then 10 mg in the morning, 5 mg in the afternoon, and 5 mg in the evening for the next three weeks.
Number of subjects: 24
Study 1573045 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 5 mg three times a day for all 4 weeks.
Number of subjects: 24
Study 1573045 — intervention group
Group type: COMPARATOR
Intervention: Placebo during the first 7 days and the last 7 days of the study.
Number of subjects: 24
Study 1573045 — intervention group
Group type: EXPERIMENTAL
Intervention: Driving performance test after each treatment week.
Number of subjects: 24
Study 3993625 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (DTIC, DTIC/CCNU/vincristine)
Number of subjects: 26
Study 3993625 — intervention group
Group type: COMPARATOR
Intervention: Control group (no further treatment after surgery)
Number of subjects: 26
Study 30981313 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluralaner (Bravecto®)
Number of subjects: 20
Study 30981313 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 20
Study 29316912 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported changes in sleep patterns (Pittsburgh Sleep Quality Index) from six weeks to seven months postpartum
Number of subjects: 122
Study 29316912 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported changes in sleep latency, daytime dysfunction, and sleep quality
Number of subjects: 122
Study 26638185 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (obesity prevention intervention embedded in parenting program)
Number of subjects: 56
Study 26638185 — intervention group
Group type: COMPARATOR
Intervention: Control (weekly mailings)
Number of subjects: 56
Study 23743209 — intervention group
Group type: COMPARATOR
Intervention: Propofol alone (group P, n=13)
Number of subjects: 26
Study 23743209 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% N2O and propofol (group N+P, n=13)
Number of subjects: 26